Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
August 10, 2026
Technology
-
-
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx’s DNA Polymerase IIIC Inhibitor Antibiotics
August 10, 2026
-
SEALSQ’s SEALQuantum Sovereign Quantum Vertical Stack Interconnects Its Growing Ecosystem as $200 Million SEALQuantum.com Initiative Enters Second Phase of Deployment in September
August 7, 2026
-
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
August 7, 2026
-
HeartCore Announces Strategic Transfer of 51% Equity Interest in HeartCore Luvina Vietnam to Luvina Software
August 7, 2026
-
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
August 7, 2026
-
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 7, 2026
-
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
August 7, 2026
-
Kane Biotech Announces Engagement of DNA Advisors
August 5, 2026
-
Kaltura Announces Financial Results for Second Quarter 2026
August 5, 2026
-
Ascent Solar Technologies Meets Growing Drone Market Demand; Reinforces Primary Space Industry Focus
August 5, 2026
-
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
August 5, 2026
-
Broadridge and Payward Services Collaborate to Give xStocks Holders a Voice in Corporate Governance
August 5, 2026
-
FTC Solar Announces Second Quarter 2026 Financial Results
August 5, 2026
-
Thryv and Ooma Announce Co-Marketing Agreement Targeting Small Businesses
August 4, 2026
-
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
August 4, 2026